Hospital services will be further improved with maternity hospitals becoming part of district general hospitals. The technology in the labour ward will further develop and feetal monitoring and regional analgesia will become a feature of the labour ward. We have still no reason to be proud of the pain relief we offer women in childbirth, and the provision of anesthetic services in maternity hospitals is still deficient. The risk of obstetric anesthesia is not fully realized and far too many anwsthetics are being given by junior and relatively inexperienced aniesthetists.
The care of the newborn should improve further. There is now ample evidence that intensive care units for the newborn, provided that they are properly equipped and staffed, can work wonders. Newborn babies can be safely transported to these units so that it is not necessary for every maternity unit to have an intensive care baby unit, but it is equally right that there should be one within reach of every mother at her delivery.
Medical students should still do a period of training in obstetrics, but many teaching hospitals are finding it difficult to supply a sufficient number of normal cases for students to undertake because of developments such as regional analgesia which may lead to a high forceps rate. Students should undertake some normal deliveries but equally they can learn from assisting at other deliveries and above all by observing the woman through the course of her labour. Postgraduate training and accreditation are now accepted, but for the future it is important that all those who undertake obstetric care should be well trained and experienced and should continue the practice of midwifery. The prospect of a pleasant, pain-free delivery for every mother of every baby in this country is almost if not completely attainable. This report deals with the basal endocrine status and response to dynamic pituitary function tests in 24 patients who had 'post-pill' amenorrhcea and formed part of a group of 190 patients investigated for secondary amenorrhcea at King's College Hospital. The detailed analysis of this group is reported elsewhere (Newton et al. 1973 ).
Patients and Methods
Each patient was admitted and basal blood and urine samples were taken for three consecutive days for measurement of luteinizing hormone (LH), follicle stimulating hormone (FSH) and cestrogens. Thyroid function was assessed by measurement of protein-bound iodine, triiodothyronine (T3 resin) and thyroxine levels. Basal cortisol levels were also measured. In addition to a general medical and endocrine assessment, a detailed psychiatric assessment was made using a standardized interview (Newton et al. 1973 ).
Height, weight and span were recorded, visual fields were charted and a cone X-ray view of the pituitary fossa was obtained. Dynamic tests of hypothalamic/pituitary function were also carried out. All patients had insulin hypoglycemia, lysine vasopressin and short Synacthen tests. In addition, the effect on FSH and LH production produced by clomiphene (the pituitary reserve test described by Newton & Dixon (1971) and Newton, Ramsay & Marsden (1971) ) and by LH-releasing hormone (LH-RH) was measured. Following these tests, a laparoscopy was carried out to assess uterine, tubal and ovarian physiology. The patients were each given, as outpatients, 5 mg medroxyprogesterone acetate daily for seven days to see if this produced a progestogenwithdrawal bleed. Plasma and urinary LH and FSH were measured by the radioimmunosorbent assay (Wide & Porath 1966) , the precision of which has been reported (Newton, Joyce, Pearce, Revell & Tyler 1971) . Urinary cestrogens were by the short method of Brown et al. (1968) . Table 1 shows the antecedent factors for the whole group of secondary amenorrhcea. There was no relationship between the length of time Norinyl-l 1 Not known 3 on oral contraception, the type of pill used and secondary amenorrhoea in this group. Table 2 shows the drugs used: 7 contained ethinyloestradiol and 9 mestranol, 14 were 19-nor-testosterone compounds, and 2 17a-hydroxyprogesterone derivatives. Five patients had used 'various' types of oral contraception rather than one type and in 3 the type was not known. The age range of these patients was 17-34 years, the length of amenorrheea 6-60 months with a mean of 13.4 months. The mean menarche was 13.6 years (normal 13.5). In 13 patients there had been persistent oligomenorrhoea (6 to 8 week cycles) since the menarche, a further 3 had irregular or anovular cycles and only 8 had a history of regular menstrual cycles prior to medication.
Clinical Details

Results
The tests of thyroid function were normal, as were the basal cortisol levels, pituitary fossa size and visual fields. Psychiatric screening showed that 6 of these patients had associated stress presenting as either anxiety or depression. Fig 1 shows the basal endocrine status relating to LH, FSH and oestrogens. Box A refers to the total amenorrheeic group of 190 patients. The gonadotrophin levels are divided up into low, normal and high values and the cestrogens into low and normal levels (see Newton (1972) for further details). A large proportion (44%) of the 190 amenorrhceic patients had low cestrogens and low gonadotrophins; 7.6 had normal cestrogens and gonadotrophins and these patients had spontaneous return of menstruation; 10.4% had high gonadotrophins and low cestrogensthe premature menopause group.
Of the 24 patients with post-pill amenorrhoea, one had high LH and FSH levels with low cestrogens, and on laparoscopy was found to have a streak gonad on one side and a small ovary on the other. Two patients had high gonadotrophins and cestrogensboth were pregnant. One patient had normal gonadotrophins and oestrogens and had spontaneous return of menstruation. Two further patients with normal gonadotrophins but low oestrogens ovulated and became pregnant following the clomiphene pituitary function test. Four patients had normal cestrogens and low gonadotrophins. All had a positive response to clomiphene pituitary reserve test with an increase in LH and FSH. Following clomiphene they had spontaneous regular menstrual cycles. The LH/ FSH-RH test was also positive and a progestogenwithdrawal bleed occurred. In the remaining 14 patients both gonadotrophins and cestrogens were low, only 4 had a positive increase in LH and FSH after a clomiphene pituitary reserve test, but no patient subsequently continued with spontaneous menstrual cycle. The LH/FSH-RH test was also positive in all cases, but no progestogen-withdrawal bleed occurred.
All insulin hypoglycwemia tests, short Synacthen tests and lysine vasopressin tests were normal in this group.
Discussion
Though secondary amenorrhaea after oral contraception is recognized (Shearman 1968 , 1971 , Shearman & Turtle 1970 , Newton 1972 , it represents only a small proportion of those patients who present with this symptom, the figure being 24 (11.6%) of 190 patients in this series.
While the majority of Shearman's patients with post-pill amenorrheea (Shearman 1971) (1968, 1971) there was no relationship between the type of contraceptive pill, length of usage and the incidence of amenorrh(ca. This tends to suggest that the mechanism of action is general rather than due to a specific combination of steroid hormones. Study of the basal endocrine status revealed normal thyroid and adrenal activity in this group. However, psychiatric assessment and investigation of gonadotrophins and aestrogen levels provided valuable information for prognosis and treatment. Similar to the total group of patients with secondary amenorrhoea (Newton et al. 1973) the majority-14 out of 24had low cestrogens and low gonadotrophins. No patient had a progestogen-withdrawal bleed with an cestrogen level of less than 15 ,ug/24 h, and of the dynamic tests of hypothalamic/pituitary function, only the clomiphene pituitary reserve test and the LH/ FSH-RH test were useful. Of the 14 patients with low cestrogens and gonadotrophins, only 4 had a positive increase in LH and FSH, indicating that the remainder probably had some derangement of hypothalamic pituitary function.
Conclusions
Twenty-four cases of post-pill amenorrhcea are presented out of 190 patients presenting with secondary amenorrhoea (11.6 %); 14 had low cestrogens and gonadotrophins; of these only 4 had a positive clomiphene pituitary reserve test. None established regular cycles. Four patients with normal estrogens and low gonadotrophins had a positive clomiphene pituitary reserve test and subsequently restarted normal cycles. LH/ FSH-RH tests showed normal pituitary function. Other dynamic tests of hypothalamic pituitary function were normal, as was the basal endocrine state of the thyroid and adrenal. The problem of whether reported episodes of amenorrheea after the combined cestrogen/ progestogen pill are coincidental or not is mainly an epidemiological one which has been largely neglected. I have searched for valid data on the incidence of post-pill amenorrhcea in the general population; the best comefromTreloar etal. (1967) and Treloar (1972, personal communication) who have recorded the variation of the human menstrual cycle through reproductive life in a series of 2702 women. Recruitment began in 1935 and follow up is still continuing. The data (Table  1) indicate that secondary amenorrhaea occurs in a significant proportion of initially healthy women Table 1 Incidence of long intervals between menstrual periods in the general population (based on data provided by Treloar, 1972, personal and that the incidence varies considerably with age. Follow up of women stopping the pill in major clinical trials has shown that the incidence of post-pill amenorrhoea is very low. Rice-Wray et al. (1967) noted two occurrences of amenorrhoea exceeding 180 days in 163 women observed for this period of time after stopping the pill. The corresponding incidence reported by Larsson-Cohn (1969) was 4 in 516 women. In his series the incidence among women with a previously regular cycle was 1 in 432. This observed incidence is not significantly greater than the expected incidence calculated on the basis of Treloar's data for all ages (observed 1; expected 0.48; P==0.40), or even on the basis of Treloar's data for patients aged 20-24 (expected 0.15; P=0.20). However, if Larsson-Cohn's data on 84 women with previously irregular menstruation are included, the observed incidence is significantly greater than that expected from Treloar's data for patients of all ages
